Date & Time: Wednesday, October 13, 2021 | 10:00 am – 11:00 am PDT
Location: Online
Presenters: Prof. Ed Schuuring, and Dr. Darryl Irwin

Hear leading experts discuss the clinical applications of circulating cell free DNA (ccfDNA) in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors or immune checkpoint inhibitors. Complete the form below to register.

Additional Topics

• Utility of circulating tumor DNA (ctDNA) as a minimally invasive molecular tool to guide treatment decisions and disease monitoring, especially when no appropriate tumor tissue biopsy is available.
• Characteristics of a suitable diagnostic-grade platform required for the detection of tumor-specific mutations with high sensitivity in ccfDNA.
• Review of a liquid biopsy lung panel for the detection of the most common predictive markers in comparison to other circulating tumor DNA (ctDNA) detection assays for NSCLC.

Prof. Schuuring and Dr. Irwin will be available to answer questions.

Presented By:

Ed Schuuring, PhD, Professor of Molecular Oncological Pathology at University Medical Center Groningen, Netherlands

Darryl Irwin, PhD, Vice President of Scientific Affairs at Agena Bioscience, Queensland, Australia

Moderator: Bob McGonnagle, Publisher, CAP TODAY